A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer

INTRODUCTION: For unresectable stage III non-small cell lung cancer (NSCLC), the standard therapy consists of chemoradiotherapy (CRT) followed by durvalumab maintenance for responding patients. The present study reports on the safety and outcome of durvalumab use after CRT in a real-world, multicent...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruni, Alessio, Scotti, Vieri, Borghetti, Paolo, Vagge, Stefano, Cozzi, Salvatore, D’Angelo, Elisa, Giaj Levra, Niccolò, Fozza, Alessandra, Taraborrelli, Maria, Piperno, Gaia, Vanoni, Valentina, Sepulcri, Matteo, Trovò, Marco, Nardone, Valerio, Lattanzi, Elisabetta, Bou Selman, Said, Bertolini, Federica, Franceschini, Davide, Agustoni, Francesco, Jereczek-Fossa, Barbara Alicja, Magrini, Stefano Maria, Livi, Lorenzo, Lohr, Frank, Filippi, Andrea Riccardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507147/
https://www.ncbi.nlm.nih.gov/pubmed/34650927
http://dx.doi.org/10.3389/fonc.2021.744956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507147/
https://www.ncbi.nlm.nih.gov/pubmed/34650927
http://dx.doi.org/10.3389/fonc.2021.744956

Ejemplares similares